Cell competition for cancer treatment with Urine Progenitor Cells
Bago, J. R.; Radhakrishnan, D.; Hrdinka, M.; Cichon, T.; Smolarczyk, R.; Charvatova, S.; Motais, B.; Giebel, S.; Hajek, R.
Show abstract
Here, we provide evidence that urine progenitor cells (UPCs) might offer a novel therapeutic strategy for treating different types of cancer. We found that UPCs have inherent antitumor properties due to cell-cell competition, and we described their mechanism of action against different tumor cell lines. In vitro time-lapse analysis showed that the UPCs have tumor tropic properties, homing to various tumor-conditioned mediums. Besides, UPCs engineered for the expression of cytotoxic agents (the Tumor Necrosis Factor ligand superfamily member 10 and Herpesvirus-thymidine kinase) significantly increased their antitumor properties against several tumor cell lines and proved to serve as highly effective drug-delivery vehicles. Finally, using a mouse model of human triple-negative breast cancer, we observed a 150-fold decrease in tumor volumes in mice treated with engineered UPCs compared to controls. Collectively, our findings demonstrate for the first time the antitumor properties of the UPCs and form a foundation to continue exploring the new concept of cell-cell competition in progenitor cells to treat different types of cancer.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 96%
- Profiling anti-apoptotic protein BCL-xL expression in U-87 MG glioblastoma cells and patient-derived tumorspheres 95%
- Identification of atypical circulating tumor cells with prognostic value in metastatic breast cancer patients 95%
Similar papers in this journal
- Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system 96%
- CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds 95%
- Promyelocytic Leukemia Protein regulates Angiogenesis and Epithelial-Mesenchymal Transition to limit metastasis in MDA-MB-231 breast cancer cells. 95%
Similar papers in this journal
- CtBP2 triggers CCN1-induced metastatic dissemination of osteosarcoma cells in a non-hypoxic microenvironment 95%
- Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response 93%
- Unveiling the role of osteosarcoma-derived secretome in premetastatic lung remodeling 93%
Similar papers in this journal
- SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity 94%
- Transcriptional repression of SOX2 by p53 in cancer cells regulates cell identity and migration 94%
- The transcription factor RIP140 regulates interferon γ signaling in breast cancer 93%
Similar papers in this journal
- Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma 95%
- Transcriptome Profiling and Characterization of Peritoneal Metastasis Ovarian Cancer Xenografts in Humanized Mice 95%
- Interferon-γ Increases Sensitivity to Chemotherapy and Provides Immunotherapy Targets in Models of Metastatic Castration-Resistant Prostate Cancer 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.